The Nanotechnology Knowledge Transfer Network (NanoKTN), one of the UK’s primary knowledge-based networks for Micro and Nanotechnologies, has announced the date of its first NanoPharm Special Interest Group (SIG) event, dedicated to looking at the opportunities for nanotechnology within the pharmaceuticals industry and the barriers to further commercial adoption.
The UK biotech and pharmaceuticals industry is a major success story, with exports of £17.2billion and a balance of trade of £6.0billion in 2008. In order to ensure the UK remains a world leader in this area, Government, academia and industry must support the next wave of technology, which can deliver the products of the future.
The NanoKTN aims to raise awareness of the current issues facing those working within the pharmaceuticals industry, including the obstacles faced by academia and business.
Presentations will explore key areas where nanotechnology offers the most opportunity to advance and improve product discovery and development and keep the UK a leading force in this exciting market. The event will look at examples of how nanotechnology has already been applied across a range of biomolecular interactions, along with an insight into the ways in which it can be integrated in the future.
Speakers confirmed for the event so far include Bill Sprigings of BioPark Hertfordshire, Dr David Parry of Cyclofluidic Ltd, Dr Demetrios Sideris of Genetic Microdevices Ltd, Gary Newman of Dolomite, and Gerry Ronan of Farfield Group plc.
All sectors of the pharmaceutical supply chain are encouraged to register for the NanoPharm SIG, including anyone working within research-based pharma, biotech and medical device companies, academics, research policy makers and anyone who is interested in learning about what nanotechnology has to offer the life sciences.
